The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Oct 2012
Clinical TrialAprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Itch is a common side-effect of treatment with anti-EGFR antibodies and tyrosine-kinase inhibitors. We designed a pilot single-centre study to assess the effects of aprepitant-a neurokinin receptor inhibitor-for management of severe pruritus induced by biological drugs. ⋯ None.